- Home
- IMRN vs RDHL Comparison
IMRN vs RDHL Comparison
Compare IMRN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- RDHL
- Stock Information
- Founded
- IMRN 1994
- RDHL 2009
- Country
- IMRN Australia
- RDHL Israel
- Employees
- IMRN N/A
- RDHL N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- RDHL Health Care
- Exchange
- IMRN Nasdaq
- RDHL Nasdaq
- Market Cap
- IMRN 14.4M
- RDHL 3.9M
- IPO Year
- IMRN N/A
- RDHL N/A
- Fundamental
- Price
- IMRN $2.16
- RDHL $1.54
- Analyst Decision
- IMRN
- RDHL
- Analyst Count
- IMRN 0
- RDHL 0
- Target Price
- IMRN N/A
- RDHL N/A
- AVG Volume (30 Days)
- IMRN 95.9K
- RDHL 1.4M
- Earning Date
- IMRN 08-29-2025
- RDHL 09-05-2025
- Dividend Yield
- IMRN N/A
- RDHL N/A
- EPS Growth
- IMRN N/A
- RDHL N/A
- EPS
- IMRN N/A
- RDHL N/A
- Revenue
- IMRN $4,777,422.00
- RDHL $9,550,000.00
- Revenue This Year
- IMRN N/A
- RDHL $381.91
- Revenue Next Year
- IMRN N/A
- RDHL N/A
- P/E Ratio
- IMRN N/A
- RDHL N/A
- Revenue Growth
- IMRN 48.63
- RDHL 157.62
- 52 Week Low
- IMRN $1.50
- RDHL $1.06
- 52 Week High
- IMRN $2.48
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- IMRN 54.62
- RDHL 42.97
- Support Level
- IMRN $2.09
- RDHL $1.50
- Resistance Level
- IMRN $2.24
- RDHL $1.90
- Average True Range (ATR)
- IMRN 0.13
- RDHL 0.15
- MACD
- IMRN -0.01
- RDHL -0.03
- Stochastic Oscillator
- IMRN 45.00
- RDHL 6.25
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.